1-22. (canceled)
23. A method of treating iron metabolism disorders comprising administering to a patient in need a preparation including compounds of the formula (I)
wherein
R1 and R2 are identical or different and are each chosen from the group consisting of:
hydrogen,
optionally substituted acyl,
optionally substituted alkyl,
optionally substituted aryl, and
optionally substituted heterocyclyl; or
R1 and R2 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 5- to 8-membered ring which can optionally contain further hetero atoms;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of:
hydrogen,
optionally substituted alkyl-, aryl- or heterocyclylsulfonyl,
optionally substituted acyl,
optionally substituted alkyl,
optionally substituted alkenyl,
optionally substituted alkynyl,
optionally substituted aryl, and
optionally substituted heterocyclyl; or
R4 and R5 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 5- to 8-membered ring which can optionally contain further hetero atoms;
or pharmaceutically acceptable salts thereof
for use in the treatment of iron metabolism disorders.
24. The method of claim 23, wherein in the compound of formula (I), R1 and R2 are identical or different and are each chosen from the group consisting of:
hydrogen,
optionally substituted alkyl,
optionally substituted aryl, and
optionally substituted heterocyclyl; or
R1 and R2 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 5- to 6-membered ring which can optionally contain further hetero atoms;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of hydrogen,
optionally substituted alkyl,
optionally substituted aryl, and
optionally substituted heterocyclyl; or
R4 and R5 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 5- to 6-membered ring which can optionally contain further hetero atoms;
or pharmaceutically acceptable salts thereof.
25. The method of claim 23, wherein the compound of formula (I) has the general formula (Ia)
and wherein
X is chosen from: O, N or CH;
R6 is chosen from the group consisting of:
hydrogen,
optionally substituted alkyl,
optionally substituted alkenyl,
optionally substituted alkynyl,
optionally substituted acyl,
optionally substituted alkoxycarbonyl,
optionally substituted amino,
optionally substituted aminocarbonyl,
optionally substituted alkyl-, aryl- or heterocyclylsulfonyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is chosen from the group consisting of:
hydrogen,
hydroxyl,
halogen,
cyano,
nitro,
carboxyl,
sulfonic acid radical (\u2014SO3H),
optionally substituted amino,
optionally substituted aminocarbonyl,
optionally substituted aminosulfonyl,
optionally substituted acyl,
optionally substituted acyloxy,
optionally substituted alkoxy,
optionally substituted alkoxycarbonyl,
optionally substituted alkyl,
optionally substituted alkenyl,
optionally substituted alkynyl,
optionally substituted aryl, and
optionally substituted heterocyclyl,
or pharmaceutically acceptable salts thereof.
26. The method of claim 25, wherein in the compound of formula (I),
X is chosen from: N or CH;
R6 is chosen from the group consisting of:
hydrogen,
optionally substituted alkyl,
optionally substituted alkenyl,
optionally substituted alkynyl,
optionally substituted acyl,
optionally substituted alkoxycarbonyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is chosen from the group consisting of:
hydrogen,
hydroxyl,
halogen,
cyano,
nitro,
carboxyl,
sulfonic acid radical (\u2014SO3H),
optionally substituted amino,
optionally substituted aminocarbonyl,
optionally substituted aminosulfonyl,
optionally substituted acyl,
optionally substituted acyloxy,
optionally substituted alkoxy,
optionally substituted alkoxycarbonyl,
optionally substituted alkyl,
optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted aryl, and
optionally substituted heterocyclyl;
or pharmaceutically acceptable salts thereof.
27. The method of claim 25, wherein in the compound of formula (I),
X is chosen from: N or CH;
R6 is chosen from the group consisting of:
hydrogen,
optionally substituted alkyl,
optionally substituted acyl,
optionally substituted alkoxycarbonyl,
optionally substituted amino,
optionally substituted aminocarbonyl,
optionally substituted alkyl-, aryl- or heterocyclylsulfonyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is chosen from the group consisting of:
hydrogen,
halogen,
optionally substituted amino,
optionally substituted acyl,
optionally substituted alkoxy,
optionally substituted alkyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of:
hydrogen,
optionally substituted alkyl,
optionally substituted aryl, and
optionally substituted heterocyclyl; or
R4 and R5 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 5- to 7-membered ring which can optionally contain further hetero atoms;
or pharmaceutically acceptable salts thereof.
28. The method of claim 25, wherein in the compound of formula (I),
X has the meaning N;
R6 is chosen from the group consisting of:
optionally substituted acyl,
optionally substituted alkyl-, aryl- or heterocyclylsulfonyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is hydrogen;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of
hydrogen or
optionally substituted alkyl, or
R4 and R5 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 6-membered ring which can optionally contain further hetero atoms.
or pharmaceutically acceptable salts thereof.
29. The method of claim 25, wherein in the compound of formula (I),
X has the meaning N;
R6 is chosen from the group consisting of:
optionally substituted acyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is hydrogen;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of:
hydrogen or
optionally substituted alkyl,
or pharmaceutically acceptable salts thereof.
30. The method of claim 23, wherein in the compound of formula (I),
X has the meaning CH; and
R6 is chosen from the group consisting of:
hydrogen,
optionally substituted alkyl,
optionally substituted alkoxycarbonyl,
optionally substituted amino,
optionally substituted aminocarbonyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is hydrogen;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of:
hydrogen,
optionally substituted alkyl; or
R4 and R5 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 6- or 7-membered ring which can optionally contain further hetero atoms;
or pharmaceutically acceptable salts thereof.
31. The method of claim 23, wherein in the compound of formula (I),
X has the meaning CH; and
R6 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is hydrogen;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of:
hydrogen,
optionally substituted alkyl; or
R4 and R5 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 6-membered ring which can optionally contain further hetero atoms;
or pharmaceutically acceptable salts thereof.
32. The method of claim 23, wherein in the compound of formula (I), R1 and R2 together with the nitrogen atom to which they are bonded form an optionally substituted, saturated or unsaturated 6-membered ring which can optionally contain one to 3 further hetero atoms andor wherein R3 is optionally substituted aryl or optionally substituted heterocyclyl.
33. The method of claim 23, wherein in the compound of formula (I), R4 and R5 are identical and denote hydrogen, or one of the radicals R4 or R5 is hydrogen, and the other radical of the radicals R4 or R5 is optionally substituted alkyl, or wherein R4 and R5 together with the nitrogen atom to which they are bonded faun an optionally substituted, saturated or unsaturated 6- or 7-membered ring which can optionally contain one to 3 further hetero atoms.
34. The method of claim 23, wherein the compound of formula (I) is selected from the group consisting of:
or pharmaceutically acceptable salts thereof.
35. The method of claim 23, wherein the disorders in iron metabolism are selected from the group consisting of: iron deficiency diseases, anaemias, anaemias with cancer, anaemia induced by chemotherapy, anaemia induced by inflammation, anaemias with congestive cardiac insufficiency, anaemia with chronic renal insufficiency stage 3-5, anaemia induced by chronic inflammation, anaemia with rheumatic arthritis, anaemia with systemic lupus erythematosus and anaemia with inflammatory intestinal diseases.
36. The method of claim 23, wherein the preparation further comprises at least one of pharmaceutical carriers, auxiliary substances, and solvents for use in the treatment of iron metabolism disorders.
37. The method of claim 23, wherein the preparation further comprises at least one further pharmaceutically active compound, which is a compound for treatment of disorders in iron metabolism and the accompanying symptoms.
38. The method of claim 23, wherein the compound for treatment of disorders in iron metabolism and the accompanying symptoms is an iron-containing compound for the use in the treatment of iron metabolism disorders.
39. The method of claim 24, wherein the compound of formula (I) has the general formula (Ia)
and wherein
X is chosen from: O, N or CH;
R6 is chosen from the group consisting of
hydrogen,
optionally substituted alkyl,
optionally substituted alkenyl,
optionally substituted alkynyl,
optionally substituted acyl,
optionally substituted alkoxycarbonyl,
optionally substituted amino,
optionally substituted aminocarbonyl,
optionally substituted alkyl-, aryl- or heterocyclylsulfonyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is chosen from the group consisting of:
hydrogen,
hydroxyl,
halogen,
cyano,
nitro,
carboxyl,
sulfonic acid radical (\u2014SO3H),
optionally substituted amino,
optionally substituted aminocarbonyl,
optionally substituted aminosulfonyl,
optionally substituted acyl,
optionally substituted acyloxy,
optionally substituted alkoxy,
optionally substituted alkoxycarbonyl,
optionally substituted alkyl,
optionally substituted alkenyl,
optionally substituted alkynyl,
optionally substituted aryl, and
optionally substituted heterocyclyl,
or pharmaceutically acceptable salts thereof.
40. The method of claim 26, wherein in the compound of formula (I),
X is chosen from: N or CH;
R6 is chosen from the group consisting of:
hydrogen,
optionally substituted alkyl,
optionally substituted acyl,
optionally substituted alkoxycarbonyl,
optionally substituted amino,
optionally substituted aminocarbonyl,
optionally substituted alkyl-, aryl- or heterocyclylsulfonyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is chosen from the group consisting of:
hydrogen,
halogen,
optionally substituted amino,
optionally substituted acyl,
optionally substituted alkoxy,
optionally substituted alkyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of:
hydrogen,
optionally substituted alkyl,
optionally substituted aryl, and
optionally substituted heterocyclyl; or
R4 and R5 together with the nitrogen atom to which they are bonded from a saturated or unsaturated, optionally substituted 5- to 7-membered ring which can optionally contain further hetero atoms;
or pharmaceutically acceptable salts thereof.
41. The method of claim 26, wherein in the compound having formula (I),
X has the meaning N;
R6 is chosen from the group consisting of:
optionally substituted acyl,
optionally substituted alkyl-, aryl- or heterocyclylsulfonyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is hydrogen;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of:
hydrogen or
optionally substituted alkyl, or
R4 and R5 together with the nitrogen atom to which they are bonded form a saturated or unsaturated, optionally substituted 6-membered ring which can optionally contain further hetero atoms.
or pharmaceutically acceptable salts thereof.
42. The method of claim 26, wherein in the compounds having the formula (I),
X has the meaning N;
R6 is chosen from the group consisting of:
optionally substituted acyl,
optionally substituted aryl, and
optionally substituted heterocyclyl;
R7 is hydrogen;
R3 is chosen from the group consisting of:
optionally substituted aryl, and
optionally substituted heterocyclyl;
R4 and R5 are identical or different and are each chosen from the group consisting of:
hydrogen or
optionally substituted alkyl,
or pharmaceutically acceptable salts thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed:
1. A trailer having a box constructed of three sides and a pivoting gate, each of the sides and the gate further comprising a plurality of substantially horizontal rails, each of the substantially horizontal rails having an opening substantially vertically therethrough, and further comprising a plurality of substantially vertical rails passing through the openings
2. The trailer of claim 1, each of the substantially horizontal rails and each of the substantially vertical rails being constructed of extruded aluminum.